Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSunpharmaceuticalindustries

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Super Six stocks that can boost your portfolio on Nov 23

      Ashish Kyal of wavesstrategy.com advises buying Petronet LNG with a target of Rs 243.

    • Sell Sun Pharma on bounce, says Hemen Kapadia

      Hemen Kapadia of KRChoksey Securities advises selling Sun Pharma on bounce.

    • Buy Sun Pharmaceutical Industries: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may buy Sun Pharmaceutical Industries.

    • Pick Tata Motors, see 15-20% return: Rahul Mohindar

      Rahul Mohindar of viratechindia.com is of the view that one can pick Tata Motors and sees 15-20 percent to come in the stock.

    • Samvat 2072: SP Tulsian sees 100% return in Samkrg Piston, target Rs 300

      SP Tulsian of sptulsian.com is of the view that one may see Samkrg Pistons and Rings test Rs 300.

    • Exit Sun Pharma at around Rs 820-850: Nooresh Merani

      Nooresh Merani of Asian Market Securities is of the view that one may exit Sun Pharmaceutical Industries at around Rs 820-850.

    • Krish Subramanyam recommends bear spread in Sun Pharma

      Krish Subramanyam of Altamount Capital is of the view that one can buy 780 Put and sell 740 Put.

    • Enter Sun Pharma on dips: Ambareesh Baliga

      Ambareesh Baliga, Independent Market Expert is of the view that one can enter Sun Pharma on dips.

    • Accumulate IPCA Labs on correction: Mayuresh Joshi

      Mayuresh Joshi of Angel Broking recommends accumulating IPCA Labs on correction.

    • Hold Dr Reddy's, Lupin, Sun Pharma in portfolio: Baliga

      Ambareesh Baliga, Independent Market Expert is of the view that one can keep Dr Reddy's Labs, Lupin and Sun Pharma in the portfolio from the pharma space.

    • Exit Sun Pharma at around Rs 940: Vishal Malkan

      Vishal Malkan of malkansview.com is of the view that one may exit Sun Pharma at around Rs 940.

    • Buy Sun Pharmaceutical Industries 860 Put: VK Sharma

      VK Sharma of HDFC Securities is of the view that one can buy Sun Pharmaceutical Industries 860 Put.

    • Invest in Alembic Pharma, says Dipan Mehta

      Dipan Mehta, Member at BSE & NSE is of the view that one can invest in Alembic Pharma.

    • Buy Lupin near to Rs 1650, Sun Pharma looks good: RK Global

      Rakesh Bansal of RK Global is of the view that one can buy Lupin at around Rs 1650 and feels that Granules India, Sun Pharmaceutical Industries and Aurobindo Pharma look good at current level.

    • Like Sun Pharmaceutical Industries, says Mayuresh Joshi

      Mayuresh Joshi of Angel Broking likes Sun Pharmaceutical and Industries from the pharma space from the risk reward and valuation perspective.

    • 6 stocks likely to see lot of action today

      Gaurav Bissa of LKP Securities advises buying HCL Technologies with a target of Rs 900.

    • Buy Sun Pharmaceutical Industries, advises Sameet Chavan

      Sameet Chavan of Angel Broking is of the view that one can buy Sun Pharmaceutical Industries as the stock can move towards Rs 940-950 over the next trading sessions.

    • Like TCS, Infosys, Tata Motors, Sun Pharma: R Venkatraman

      R Venkatraman, MD at IIFL Group likes Tata Consultancy Services and Infosys in IT space, Maruti Suzuki and Tata Motors from the auto space and Sun Pharmaceutical Industries and Torrent Pharmaceuticals from the pharma space.

    • Jyotivardhan Jaipuria bullish on pharma space in near term

      Jyotivardhan Jaipuria of Market Veteran is bullish on pharma space in the near term.

    • Buy Sun Pharma on dips, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Sun Pharma on dips.

    • Aurobindo Pharma, Sun Pharma preferred picks: Joshi

      Mayuresh Joshi of Angel Broking is of the view that Aurobindo Pharma and Sun Pharma are the preferred picks.

    • Buy Sun Pharma, may climb towards Rs 940-950: Sameet Chavan

      Sameet Chavan of Angel Broking recommends buying Sun Pharma on any dip for a target of Rs 940-950.

    • Dr Reddy's Labs top pick, says Mehraboon Irani

      Mehraboon Irani of Nirmal Bang Securities is of the view that Dr Reddy's Labs is the top pick.

    • Like pharma, consumer stocks: Gautam Sinha Roy

      Gautam Sinha Roy of Motilal Oswal Mutual Fund likes pharma and IT stocks.

    • Optimistic on Sun Pharma, target Rs 950: Mayuresh Joshi

      Mayuresh Joshi, Fund Manager (PMS) at Angel Broking is extremely optimistic on Sun Pharma with a target of Rs 950.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347